Advertisement
Advertisement
PHAR
Pharming Group N.V. ADS, each representing 10 ordinary shares
12.97
USDSponsored
-0.12
-0.92%
May 13, 16:00 UTC -4
Closed
Pre-Market
13.39
+0.42
+3.28%
PHAR Earnings Reports
Positive Surprise Ratio
PHAR beat 20 of 41 last estimates.
49%
Next Report
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$105.99M
/$0.01
Implied change from Q1 26 (Revenue/ EPS)
+46.30%
/--
Implied change from Q2 25 (Revenue/ EPS)
+13.72%
/--
Pharming Group N.V. ADS, each representing 10 ordinary shares earnings per share and revenue
On May 07, 2026, PHAR reported earnings of 0.00 USD per share (EPS) for Q1 26, missing the estimate of 0.00 USD, resulting in a -204.48% surprise. Revenue reached 72.45 million, compared to an expected 96.56 million, with a -24.97% difference. The market reacted with a -26.83% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 0.01 USD, with revenue projected to reach 105.99 million USD, implying an -- of --% EPS, and increase of 46.30% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Pharming Group N.V. ADS, each representing 10 ordinary shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Pharming Group N.V. ADS, each representing 10 ordinary shares reported EPS of $0.00, missing estimates by -204.48%, and revenue of $72.45M, -24.97% below expectations.
How did the market react to Pharming Group N.V. ADS, each representing 10 ordinary shares's Q1 2026 earnings?
The stock price moved down -26.83%, changed from $16.40 before the earnings release to $12.00 the day after.
When is Pharming Group N.V. ADS, each representing 10 ordinary shares expected to report next?
The next earning report is scheduled for Jul 30, 2026.
What are the forecasts for Pharming Group N.V. ADS, each representing 10 ordinary shares's next earnings report?
Based on 4
analysts, Pharming Group N.V. ADS, each representing 10 ordinary shares is expected to report EPS of $0.01 and revenue of $105.99M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement